Teva (TEVA): Soft 2Q Underscores Need For Actavis - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- S&P, Dow open flat as Middle East jitters ease, Netflix weighs on Nasdaq
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Stocks off two-month low as fear of Middle East escalation eases
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- Netflix, Tesla, Amex, P&G fall premarket; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Mizuho Securities Cuts Price Target on Teva Pharma (TEVA) Following 2Q Beat
August 8, 2016 6:53 AM EDTMizuho Securities maintained a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $70.00 (from $75.00), following the company's 2Q earnings report. TEVA reported revenue of $5.0B and $1.25 EPS, vs. $4.88B and $1.20 consensus and management's recent guidance of $4.9- $5.0B and... More
Oppenheimer Downgrades Teva Pharma (TEVA) to Perform
August 5, 2016 7:27 AM EDTOppenheimer downgraded Teva Pharma (NYSE: TEVA) from Outperform to Perform and removed its price target (prior $72.00).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $55.45 yesterday.
... MoreTeva Pharma (TEVA) Tops Q2 EPS by 5c; Guides In-Line
August 4, 2016 7:05 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $1.25, $0.05 better than the analyst estimate of $1.20. Revenue for the quarter came in at $5 billion versus the consensus estimate of $4.87 billion.
We are pleased with our performance this quarter and the steps we are taking to transform our business, notably the recent... More
